OBs Have New Technology to Help Reduce SIDS

Apr 25, 2001, 01:00 ET from Cord Blood Registry

    SAN BRUNO, Calif., April 25 /PRNewswire/ -- A new expanded newborn
 screening test may help prevent infant deaths that are diagnosed as sudden
 infant death syndrome (SIDS). Cbr's NewScreen(TM): Expanded Newborn Screening,
 which is being launched at the ACOG Annual Clinical Meeting in Chicago
 April 28-May 2, 2001, can detect many fatty acid oxidation disorders which,
 according to research in The Journal of Pediatrics (132:6), may comprise up to
 5 percent of SIDS cases.
     Thousands of children die every year from SIDS, the third leading cause of
 infant death in the United States. According to the SIDS Network,
 "more children die of SIDS in a year than all who die of cancer, heart
 disease, pneumonia, child abuse, AIDS, cystic fibrosis, and muscular dystrophy
 combined."
     Fatty acid disorders are just one subset of more than 40 disorder
 classifications that can be detected by NewScreen, making it the most
 comprehensive newborn screening test available to parents. On average, states
 only mandate testing for six disorders and very few require any screening for
 fatty acid disorders, which means thousands of babies slip through the cracks
 every year.
     Brett Revinski of Central Valley, NY was one of those babies. He spent
 2 months on life-support before doctors discovered he had a fatty acid
 oxidation disorder. "If my doctor had told me about newborn screening, I would
 have agreed to pay for the test out of pocket in an instant," says Brett's
 mom, Gina Revinski.
     Using biochemical assays and powerful new technology for newborn screening
 called tandem mass spectrometry, NewScreen is a simple screening test that
 uses a blood sample taken at the same time as a newborn's routine "heel-stick"
 in the first few days of life. The introduction of NewScreen marks the first
 nation-wide campaign to bring this new technology to expectant parents and to
 increase awareness about the importance of expanded newborn screening for
 infant health. NewScreen is available for less than $100.
     NewScreen is a time-sensitive test and it is important for expectant
 parents to make arrangements before they give birth. One in every 1,500 babies
 are born with a disorder that can be detected with NewScreen. Caregivers and
 parents can learn more about NewScreen by visiting
 http://www.newscreentest.com .
     Please visit our booth (1754) at the ACOG Annual Clinical Meeting for more
 information and press materials.
 
     CONTACT:  Sam Yoo, 800-747-3319, ext. 239, or syoo@cordblood.com, or Amy
 Seirer, 800-747-3319, ext. 303, or aseirer@cordblood.com, both of Cord Blood
 Registry.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X05142051
 
 

SOURCE Cord Blood Registry
    SAN BRUNO, Calif., April 25 /PRNewswire/ -- A new expanded newborn
 screening test may help prevent infant deaths that are diagnosed as sudden
 infant death syndrome (SIDS). Cbr's NewScreen(TM): Expanded Newborn Screening,
 which is being launched at the ACOG Annual Clinical Meeting in Chicago
 April 28-May 2, 2001, can detect many fatty acid oxidation disorders which,
 according to research in The Journal of Pediatrics (132:6), may comprise up to
 5 percent of SIDS cases.
     Thousands of children die every year from SIDS, the third leading cause of
 infant death in the United States. According to the SIDS Network,
 "more children die of SIDS in a year than all who die of cancer, heart
 disease, pneumonia, child abuse, AIDS, cystic fibrosis, and muscular dystrophy
 combined."
     Fatty acid disorders are just one subset of more than 40 disorder
 classifications that can be detected by NewScreen, making it the most
 comprehensive newborn screening test available to parents. On average, states
 only mandate testing for six disorders and very few require any screening for
 fatty acid disorders, which means thousands of babies slip through the cracks
 every year.
     Brett Revinski of Central Valley, NY was one of those babies. He spent
 2 months on life-support before doctors discovered he had a fatty acid
 oxidation disorder. "If my doctor had told me about newborn screening, I would
 have agreed to pay for the test out of pocket in an instant," says Brett's
 mom, Gina Revinski.
     Using biochemical assays and powerful new technology for newborn screening
 called tandem mass spectrometry, NewScreen is a simple screening test that
 uses a blood sample taken at the same time as a newborn's routine "heel-stick"
 in the first few days of life. The introduction of NewScreen marks the first
 nation-wide campaign to bring this new technology to expectant parents and to
 increase awareness about the importance of expanded newborn screening for
 infant health. NewScreen is available for less than $100.
     NewScreen is a time-sensitive test and it is important for expectant
 parents to make arrangements before they give birth. One in every 1,500 babies
 are born with a disorder that can be detected with NewScreen. Caregivers and
 parents can learn more about NewScreen by visiting
 http://www.newscreentest.com .
     Please visit our booth (1754) at the ACOG Annual Clinical Meeting for more
 information and press materials.
 
     CONTACT:  Sam Yoo, 800-747-3319, ext. 239, or syoo@cordblood.com, or Amy
 Seirer, 800-747-3319, ext. 303, or aseirer@cordblood.com, both of Cord Blood
 Registry.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X05142051
 
 SOURCE  Cord Blood Registry

RELATED LINKS

http://www.cordblood.com/about.html